Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model

Abstract Objective: Tamoxifen (TAM) is widely employed in the treatment of breast malignancies and is also found to be effective in psoriasis treatment. The current studies aimed to explore the antipsoriatic potential of topical TAM encapsulated in the new generation phospholipid-based vesicular and micellar systems, i.e. flexible membrane vesicles (FMVs) and pluronic lecithinized organogels (PLOs). Methods: TAM-loaded-FMVs were prepared by thin-film hydration technique, while TAM–PLOs were prepared by simple mixing. Mouse-tail model was used to evaluate the antipsoriatic activity of the novel formulations. The mouse tails were treated once-a-day with different formulations for a period of four weeks and prepared for longitudinal histological sections by hematoxylin–eosin staining technique. The length of the orthokeratotic regions in stratum granulosum was measured on 10 sequential scales per tail section as percentage of the full length of the scale, and the drug activity was calculated further. Results: Evaluation of antipsoriatic activity on mice tail revealed significantly higher (p < 0.01) efficacy of TAM–FMV gel (i.e. 35.8%) and TAM–PLO (i.e. 24.6%) vis-à-vis the conventional TAM–hydrogel (i.e. 10.2%). Conclusions: The results of these studies demonstrated immense potential of the topically applied TAM-encapsulated vesicular and micellar systems in psoriasis, thus calling for more comprehensive investigations to establish the role of TAM in the management of psoriasis.

[1]  Bhupinder Singh,et al.  Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes , 2013, Journal of microencapsulation.

[2]  A. Shukla,et al.  Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis , 2012, Journal of drug targeting.

[3]  D. Paolino,et al.  Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. , 2012, International journal of pharmaceutics.

[4]  Bhupinder Singh,et al.  Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin , 2011, Journal of drug targeting.

[5]  Bartosz A Grzybowski,et al.  Vesicle-to-micelle oscillations and spatial patterns. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[6]  K. McMasters,et al.  Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer , 2010, Cancer.

[7]  Carmen L. Lewis,et al.  Effectiveness of a patient‐ and practice‐level colorectal cancer screening intervention in health plan members , 2010, Cancer.

[8]  S. Bhushan,et al.  Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. , 2009, Drug development and industrial pharmacy.

[9]  J. Prat,et al.  Uterine sarcomas: a review. , 2010, Gynecologic Oncology.

[10]  Bhupinder Singh,et al.  Phospholipid‐based formulation with improved attributes of coal tar , 2009, Journal of cosmetic dermatology.

[11]  S. Ferrero,et al.  Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. , 2008, Breast.

[12]  R. Kumar,et al.  Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: A review , 2005, AAPS PharmSciTech.

[13]  R. Tripathi,et al.  Drug-Induced Ocular Disorders , 2008, Drug safety.

[14]  Bhupinder Singh Bhoop,et al.  Tamoxifen in pluronic lecithin organogel: A novel topical approach for cancer treatment. , 2007 .

[15]  R. Hayashi,et al.  Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors , 2007, Oncogene.

[16]  R. Barakat,et al.  Comparison of uterine malignancies that develop during and following tamoxifen therapy. , 2006, Gynecologic oncology.

[17]  Christopher P. Thomas,et al.  Preferential π–π complexation between tamoxifen and borage oil/γ linolenic acid: transcutaneous delivery and NMR spectral modulation , 2005 .

[18]  Amit Bhatia,et al.  Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. , 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[19]  P. Brown,et al.  Should Tamoxifen Be Used in Breast Cancer Prevention? , 2004, Drug safety.

[20]  W. Cunliffe,et al.  Effect of crude coal tar in the mouse-tail model of psoriasis , 2004, Archives of Dermatological Research.

[21]  G. Cevc,et al.  Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. , 2003, Biochimica et biophysica acta.

[22]  S. Chan A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. , 2002, Seminars in oncology.

[23]  G. Hortobagyi,et al.  Progress in breast cancer chemoprevention. , 2002, Endocrine-related cancer.

[24]  H. Hoffmann,et al.  Lecithin Organogel with New Rheological and Scaling Behavior , 2001 .

[25]  L. King,et al.  Tamoxifen-induced remission of psoriasis. , 1999, Journal of the American Academy of Dermatology.

[26]  G. Cevc Overcoming the Skin Barrier with Artificial Smart Carriers of Drugs , 1999 .

[27]  A. Jirillo,et al.  Psoriasis and tamoxifen therapy: a case report. , 1996, Tumori.

[28]  G. Cevc Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[29]  H. Jacobs,et al.  Cyclical psoriatic arthritis responding to anti‐oestrogen therapy , 1993, The British journal of dermatology.

[30]  T. Matthiesen,et al.  A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[31]  M. Greaves,et al.  Evaluation of a therapeutic concentration of dithranol in the mouse‐tail test , 1988, The British journal of dermatology.

[32]  J. Pasqualini,et al.  Estrogen and progesterone receptors in the fetal and newborn vagina of guinea pig: biological, morphological, and ultrastructural responses to tamoxifen and estradiol. , 1986, Endocrinology.

[33]  J. Pasqualini,et al.  Biological responses of tamoxifen in the fetal and newborn vagina and uterus of the guinea-pig and in the R-27 mammary cancer cell line. , 1986, Journal of steroid biochemistry.

[34]  B. Ninham,et al.  Micelles, vesicles and microemulsions , 1981 .

[35]  A. Britten,et al.  Evaluation of coal tar fractions for use in psoriasiform diseases using the mouse tail test , 1975, The British journal of dermatology.

[36]  A. Britten,et al.  Evaluation of coal tar fractions for use in psoriasiform diseases using the mouse tail test , 1975, The British journal of dermatology.